Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases.

Önal, UĞUR; Akyol, Deniz; Kaya, Arda; Başkol, Dilşah; Kenanoglu, Buse; Şanlıdağ, Gamze; Önal, Ayşe; Avşar, Cansu; Mert, Merve; Memetali, Seichan; Erdem, Hüseyin; Bozkurt, Devrim; Şimşir, Adnan; Bozbıyık, Osman; Kahraman, Ümit; Özgiray, Erkin; Korkmaz, Pervin; Çilli, Feriha; Pullukçu, Hüsnü; Yamazhan, Tansu; Taşbakan, Meltem; Arda, Bilgin; Ulusoy, Sercan; Sipahi, Oğuz

doi:10.1007/s10096-023-04660-3

Ertapenem plus meropenem combination treatment in carbapenem-resistant Klebsiella pneumoniae bacteremia: an analysis of 53 cases.

Önal U., Akyol D., Kaya A., Başkol D., Kenanoglu B., Şanlıdağ G., ...Daha Fazla

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, cilt.42, ss.1269-1273, 2023 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 42
Basım Tarihi: 2023
Doi Numarası: 10.1007/s10096-023-04660-3
Dergi Adı: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, Environment Index, MEDLINE, Public Affairs Index, Veterinary Science Database
Sayfa Sayıları: ss.1269-1273
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.